Dr. Susanne Schaffert has 25 years of experience in Pharmaceuticals, specializing in Oncology. As the former President of Novartis Oncology, she led a broad portfolio, including the first CAR-T cell therapy in hematology and the launch of the first two radio ligand therapies in solid tumors. She managed 10,000 associates, achieving $15bn in annual sales. Recognized by Fortune as one of the Top 100 Most Powerful Women in 2019 and 2020, she now serves on multiple biotech boards, including Merck Group, Incyte Corporation, Novo Holdings, Galapagos, ARTBio Inc., and Vetter Pharma. She holds a PhD in Chemistry from the University of Erlangen, Germany.